Literature DB >> 22581411

Gadoxetic acid-enhanced T1-weighted MR cholangiography in primary sclerosing cholangitis.

Alex Frydrychowicz1, Andrzej R Jedynak, Frederick Kelcz, Scott K Nagle, Scott B Reeder.   

Abstract

PURPOSE: To investigate the value of gadoxetic acid-enhanced three-dimensional T1-weighted MR cholangiography (T1w-MRC) in comparison to three-dimensional T2-weighted MR cholangiopancreaticography (T2w-MRCP) in patients with primary sclerosing cholangitis (PSC).
MATERIALS AND METHODS: Thirty-four MR exams in 29 patients (46.0 ± 16.1 years; 19 men, 10 women) scanned within a 14-month period were retrospectively included. Two abdominal radiologists independently evaluated image quality regarding image contrast, image quality degradation due to artifacts, and visualization quality of ducts. The order of biliary tree branches that were visualized and reader preference toward each method were recorded. Helpfulness of T1w-MRC was scored in consensus. Confirmatory endoscopic retrograde cholangiopancreaticography (ERCP) performed within 3 months of the MR examination was available in 8 patients.
RESULTS: Image quality of T1w-MRC and T2w-MRCP was graded good to excellent in all cases. There were advantages for both T1w-MRC (functional information, less degradation due to artifacts) and T2w-MRCP (higher order of visualized branches, better branch depiction). Both readers showed preference for T2w-MRCP; however, both readers found gadoxetic acid-enhanced T1w-MRC helpful in the majority of cases.
CONCLUSION: Gadoxetic acid-enhanced T1w-MRC is complementary to, but should not replace, T2w-MRCP. T1w-MRC is a useful adjunct to T2w-MRCP for morphologic evaluation and provides additional diagnostic information.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22581411      PMCID: PMC3419782          DOI: 10.1002/jmri.23683

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  24 in total

1.  MR cholangiopancreatography in patients with primary sclerosing cholangitis: interobserver variability and comparison with endoscopic retrograde cholangiopancreatography.

Authors:  K M Vitellas; A El-Dieb; K K Vaswani; W F Bennett; M Tzalonikou; C Mabee; R Kirkpatrick; J G Bova
Journal:  AJR Am J Roentgenol       Date:  2002-08       Impact factor: 3.959

Review 2.  Aetiology and natural history of primary sclerosing cholangitis--a decade of progress?

Authors:  R W Chapman
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

3.  Coronary angiography with magnetization-prepared T2 contrast.

Authors:  J H Brittain; B S Hu; G A Wright; C H Meyer; A Macovski; D G Nishimura
Journal:  Magn Reson Med       Date:  1995-05       Impact factor: 4.668

Review 4.  Primary sclerosing cholangitis.

Authors:  Y M Lee; M M Kaplan
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

5.  Abdominal MR imaging with a volumetric interpolated breath-hold examination.

Authors:  N M Rofsky; V S Lee; G Laub; M A Pollack; G A Krinsky; D Thomasson; M M Ambrosino; J C Weinreb
Journal:  Radiology       Date:  1999-09       Impact factor: 11.105

6.  Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation.

Authors:  M Bollow; M Taupitz; B Hamm; T Staks; K J Wolf; H J Weinmann
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

7.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.

Authors:  B Hamm; T Staks; A Mühler; M Bollow; M Taupitz; T Frenzel; K J Wolf; H J Weinmann; L Lange
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

8.  Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system.

Authors:  G Schuhmann-Giampieri; H Schmitt-Willich; W R Press; C Negishi; H J Weinmann; U Speck
Journal:  Radiology       Date:  1992-04       Impact factor: 11.105

9.  Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.

Authors:  O Clément; A Mühler; V Vexler; Y Berthezène; R C Brasch
Journal:  Invest Radiol       Date:  1992-08       Impact factor: 6.016

10.  Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.

Authors:  P Reimer; E J Rummeny; K Shamsi; T Balzer; H E Daldrup; B Tombach; T Hesse; T Berns; P E Peters
Journal:  Radiology       Date:  1996-04       Impact factor: 11.105

View more
  9 in total

1.  Added value of gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography for the diagnosis of post-transplant biliary complications.

Authors:  Sonja Kinner; Tilman B Schubert; Adnan Said; Joshua D Mezrich; Scott B Reeder
Journal:  Eur Radiol       Date:  2017-04-13       Impact factor: 5.315

2.  An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging.

Authors:  Utaroh Motosugi; Peter Bannas; Candice A Bookwalter; Katsuhiro Sano; Scott B Reeder
Journal:  Radiology       Date:  2015-10-16       Impact factor: 11.105

3.  Potential of Gd-EOB-DTPA-enhanced MR imaging for evaluation of bile duct ligation-induced liver injury in rabbits.

Authors:  Ying Ding; Sheng-Xiang Rao; Caizhong Chen; Renchen Li; Meng-Su Zeng
Journal:  Hepatol Int       Date:  2014-12-06       Impact factor: 6.047

4.  The Impact of Gd-Eob-Dtpa-Enhanced MR Cholangiography in Biliary Diseases: Comparison with T2-Weighted MR Cholangiopancreatography.

Authors:  Evrim Özmen; Oktay Algın; Şehnaz Evrimler; Halil Arslan
Journal:  Balkan Med J       Date:  2016-05-01       Impact factor: 2.021

5.  Optimal timing and diagnostic adequacy of hepatocyte phase imaging with gadoxetate-enhanced liver MRI.

Authors:  Mustafa R Bashir; Steven R Breault; Ryan Braun; Richard K Do; Rendon C Nelson; Scott B Reeder
Journal:  Acad Radiol       Date:  2014-04-06       Impact factor: 3.173

6.  Effect of hepatocyte-specific gadolinium-based contrast agents on hepatic fat-fraction and R2(⁎).

Authors:  Diego Hernando; Shane A Wells; Karl K Vigen; Scott B Reeder
Journal:  Magn Reson Imaging       Date:  2014-10-13       Impact factor: 2.546

7.  Comparison of different magnetic resonance cholangiography techniques in living liver donors including Gd-EOB-DTPA enhanced T1-weighted sequences.

Authors:  Sonja Kinner; Verena Steinweg; Stefan Maderwald; Arnold Radtke; Georgios Sotiropoulos; Michael Forsting; Tobias Schroeder
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

8.  Feasibility of gadoxetate disodium enhanced 3D T1 MR cholangiography (MRC) with a specific inversion recovery prepulse for the assessment of the hepatobiliary system.

Authors:  Ute Lina Fahlenkamp; Lisa Christine Adams; Sarah Maria Böker; Günther Engel; Minh Huynh Anh; Moritz Wagner; Bernd Hamm; Marcus Richard Makowski
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

9.  Clinical guidelines for primary sclerosing cholangitis 2017.

Authors:  Hiroyuki Isayama; Susumu Tazuma; Norihiro Kokudo; Atsushi Tanaka; Toshio Tsuyuguchi; Takahiro Nakazawa; Kenji Notohara; Suguru Mizuno; Nobuhisa Akamatsu; Masahiro Serikawa; Itaru Naitoh; Yoshiki Hirooka; Toshifumi Wakai; Takao Itoi; Tomoki Ebata; Shinji Okaniwa; Terumi Kamisawa; Hiroki Kawashima; Atsushi Kanno; Keiichi Kubota; Masami Tabata; Michiaki Unno; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-06-27       Impact factor: 7.527

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.